Table 2 Six-month cost analysis comparison of the expected costs of enoxaparin and fondaparinux over six months (estimates relate to a patient with “average” characteristics [4], adapted from Table 2 in US analysis’)
Cost of eventb (95 % Cl) | Probability of event (95 % Cl) | Cost per patientc (95 % Cl) (2009 CADS) | |||
|---|---|---|---|---|---|
Event/resource use | (2009 CAD $) | Enoxaparin | Fondaparinux | Enoxaparin | Fondaparinux |
Death | −691 (−4943, 3487) | 0.046 (0.042, 0.050) | 0.041 (0.038, 0.045) | −28 (−225, 157) | −2 5 (−203, 141) |
Non-fata Ml | 15,021 (10,997, 19,053) | 0.049 (0.046, 0.055) | 0.047 (0.043, 0.052) | 752 (527, 978) | 712 (505, 927) |
Non-fatal stroke | 18,755 (10,698, 26,864) | 0.011 (0.009, 0.014) | 0.007 (0.006, 0.009) | 217 (113, 340) | 141 (76, 226) |
Non-fatal Ml & Stroke | 3407 (−29,232, 35,980) | 0.0006 (0.0005, 0.0007) | 0.0003 (0.0003, 0.0005) | 2 (−17, 20) | 1 (−10, 13) |
Major bleed | 17,553 (13,827, 21,023) | 0.052 (0.048, 0.057) | 0.038 (0.034, 0.042) | 921 (728, 1126) | 665 (524, 823) |
Minor bleed | 3604 (171, 7182) | 0.071 (0.066, 0.077) | 0.036 (0.032, 0.040) | 257 (10, 521) | 129 (5, 254) |
Enoxaparin Treatment | 60 | 1 | 0 | 60 | 0 |
Fondaparinux Treatment | 63 | 0 | 1 | 0 | 63 |
Other costsd | 24,143 (22,785, 25,425) | 1 | 1 | 24,143 (22,785, 25,425) | 24,143 (22,785, 25,425) |
Tota mean cost | 26,302 (25,042, 27,473) | 25,864 (24,689, 27,025) | |||
Difference in mean costs | $-439 (−2069, 1322) | ||||